builderall

CONFERENCE INFORMATION

CONFERENCE DESCRIPTION

Masters in Therapeutic Oncology Summit: Lung Edition (MaTOS Lung) is a dynamic 3-day conference led by top experts in thoracic oncology. This summit delivers in-depth, multidisciplinary discussions on the most pressing challenges and future directions in lung cancer care. Participants will explore cutting-edge advances in molecular profiling, immunotherapy, targeted therapy, minimal residual disease (MRD), and emerging technologies in screening and monitoring.

Engaging panel sessions and case-based dialogue will emphasize the integration of new data into current standards of care, including the classification and clinical application of adjuvant and neoadjuvant therapies. Attendees will leave with actionable insights that can immediately inform their practice and improve patient outcomes.

KEY POINTS INCLUDE:

  • Emerging therapeutic strategies in thoracic oncology, including targeted agents and immunotherapies

  • Implementation of lung cancer screening programs using imaging, liquid biopsies, and novel biomarkers

  • Multidisciplinary evaluation of new clinical data and its integration into treatment pathways

  • Critical appraisal of newly approved agents and evolving standards in metastatic and early-stage disease

LEARNER OBJECTIVES

After participating in MaTOS Lung, learners will be better able to:

  • Interpret recent findings in lung cancer genetics and epigenomics to improve diagnosis, MRD detection, and monitoring of therapeutic response.

  • Describe the latest drug developments in thoracic oncology and their relevance to clinical decision-making.

  • Apply current evidence-based lung cancer screening strategies, including imaging and liquid biopsy techniques, to enhance early detection.

  • Incorporate new multidisciplinary findings into current standards of care for lung cancer treatment.

  • Critically appraise newly approved therapies and clinical trial data in lung cancer care to optimize treatment planning across disease stages.

  • Differentiate among current data regarding the application of adjuvant and/or  neoadjuvant, chemotherapy and immunotherapy for metastatic lung cancer.

  • Select appropriate current regimens based on patient and tumor characteristics for newly diagnosed patients.